AstraZeneca agrees to buy US FDA Priority Review Voucher from Sobi
AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsidiary of Swedish…
Read More...
Read More...